Market Overview

UPDATE: Deutsche Bank Upgraded, Raised Target on Sarepta, No Competition in Sight for Co.

BofA Downgrades Sarepta, But Hikes Price Target
Morning Market Losers
Seeking Alpha's Biotech Weekly: J&J-Achillion Vs. Gilead, MannKind's Marketing, And More (Seeking Alpha)

In a report published Friday, Deutsche Bank Markets Research analyst Robyn Karnauskas upgraded Sarepta (NASDAQ: SRPT) to Buy and increased the PT to $71.

Karnauskas noted that Drisapersen didn't hit primary endpoints and older boys responded worse with treatment. This phase III trial failure of Drisapersen removes any competitive overhang for SRPT as Sarepta will get approval for Eteplirsen. The analyst wrote, “We think Eteplirsen can get a higher 80% share in Exon-51 DMD and assign 75% probability to success in both US and EU (we were previously assigning 0% probability to EU).”

Deutsche Bank pointed to “sensitivities over the long-run suggest FV in the $98-125/sh range” with a possible $88 increase given success of exon program.

SRPT closed at $43.30 on Friday, up more than 18 percent for the session.

Latest Ratings for SRPT

May 2015Bank of AmericaDowngradesBuyNeutral
May 2015SunTrust Robinson HumphreyUpgradesNeutralBuy
May 2015Canaccord GenuityUpgradesHoldBuy

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Analyst Color News Upgrades Price Target Analyst Ratings


Related Articles (SRPT)

Around the Web, We're Loving...